PMID- 37314665 OWN - NLM STAT- MEDLINE DCOM- 20230810 LR - 20231011 IS - 1434-9949 (Electronic) IS - 0770-3198 (Print) IS - 0770-3198 (Linking) VI - 42 IP - 9 DP - 2023 Sep TI - Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus. PG - 2321-2334 LID - 10.1007/s10067-023-06649-x [doi] AB - INTRODUCTION/OBJECTIVES: The ASCORE study on treatment for rheumatoid arthritis (RA) showed better retention and clinical response rates for abatacept as first-line versus later-line therapy. This post hoc analysis of ASCORE assessed 2-year retention, efficacy, and safety of subcutaneous (SC) abatacept in Germany, Austria, and Switzerland. METHODS: Adults with RA who initiated SC abatacept 125 mg once weekly were assessed. Primary endpoint was abatacept retention rate at 2 years. Secondary endpoints: proportions of patients with low disease activity (LDA)/remission per Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (/= two prior biologics. CONCLUSION: A higher proportion of patients with + / + RA (compared with - / - RA) had abatacept retention after 2 years. Early identification of patients with seropositive RA may facilitate a precision-medicine approach to RA treatment, leading to a higher proportion of patients in LDA/remission. TRIAL REGISTRATION NUMBER: NCT02090556; date registered: March 18, 2014 (retrospectively registered). Key Points * This post hoc analysis of a German-speaking subset of European patients with RA from the global ASCORE study (NCT02090556) showed that retention of SC abatacept within this subset was 47.6%, with good clinical outcomes after 2 years. * Patients with double-seropositive RA (ACPA and RF positive) had higher retention of abatacept than patients with double-seronegative RA (ACPA and RF negative). Retention and clinical responses were highest for patients who were biologic-naive compared with patients who had one or >/= two prior biologic treatments. * These real-world data may be useful for clinicians in informing individualized treatment pathways for patients with RA, and fostering superior disease control and clinical outcomes. CI - (c) 2023. The Author(s). FAU - Alten, Rieke AU - Alten R AUID- ORCID: 0000-0002-3395-4412 AD - Department of Internal Medicine, Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Heubnerweg 2, 14059, Berlin, Germany. Rieke.Alten@schlosspark-klinik.de. FAU - Tony, Hans-Peter AU - Tony HP AD - Medizinische Klinik Und Poliklinik II, Rheumatologie/Klinische Immunologie, Universitatsklinikum Wurzburg, Josef-Schneider-Strasse 2, 97080, Wurzburg, Germany. FAU - Bannert, Bettina AU - Bannert B AD - Rheumatologische Universitatsklinik, Universitatsspital Basel, Petersgraben 4, 4031, Basel, Switzerland. FAU - Nusslein, Hubert AU - Nusslein H AD - Medic-Center Nurnberg (Private Practice), Gibitzenhofstrasse 150, 90443, Nuremberg, Germany. FAU - Rauch, Christiane AU - Rauch C AD - Medical Immunology & Fibrosis, Bristol Myers Squibb, Arnulfstrasse 29, 80636, Munich, Germany. FAU - Connolly, Sean E AU - Connolly SE AD - Immunology and Fibrosis/Global Drug Development, Bristol Myers Squibb, 3401 Princeton Pike, NJ, 08540, Lawrenceville, USA. FAU - Chartier, Melanie AU - Chartier M AD - MESP France - Market Access, Bristol Myers Squibb, 3 Rue Joseph Monier, 92506, Rueil-Malmaison, France. FAU - Lozenski, Karissa AU - Lozenski K AD - Immunology and Fibrosis/Global Drug Development, Bristol Myers Squibb, 3401 Princeton Pike, NJ, 08540, Lawrenceville, USA. FAU - Hackl, Roland AU - Hackl R AD - Immuno-Oncology, Bristol Myers Squibb, Handelskai 92/Rivergate/Gate 1, 5. OG, 1200, Vienna, Austria. FAU - Forster, Adrian AU - Forster A AD - Department of Rheumatology, Schulthess Klinik, Lengghalde 2, 8008, Zurich, Switzerland. FAU - Peichl, Peter AU - Peichl P AD - Department of Internal Medicine, Evangelical Hospital, Hans-Sachs-Gasse 10-12, 1180, Vienna, Austria. LA - eng SI - ClinicalTrials.gov/NCT02090556 PT - Journal Article DEP - 20230614 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 7D0YB67S97 (Abatacept) RN - 0 (Antirheumatic Agents) SB - IM MH - Adult MH - Humans MH - Abatacept MH - *Antirheumatic Agents/adverse effects MH - Austria MH - Switzerland MH - Treatment Outcome MH - *Arthritis, Rheumatoid MH - Germany PMC - PMC10412468 OTO - NOTNLM OT - Abatacept OT - Clinical response OT - Retention OT - Rheumatoid arthritis OT - Serostatus OT - bDMARD COIS- RA has received consulting fees from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and Roche; and has received grant/research support from Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and Roche. BB, PP, AF, and HN declare no competing interests. CR (at time of analysis), MC, SEC, RH, and KL are employees of and shareholders in Bristol Myers Squibb. H-PT has received consulting fees from AbbVie, Bristol Myers Squibb, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, and Roche. EDAT- 2023/06/14 13:07 MHDA- 2023/08/10 06:42 PMCR- 2023/06/14 CRDT- 2023/06/14 11:13 PHST- 2023/02/27 00:00 [received] PHST- 2023/05/25 00:00 [accepted] PHST- 2023/05/17 00:00 [revised] PHST- 2023/08/10 06:42 [medline] PHST- 2023/06/14 13:07 [pubmed] PHST- 2023/06/14 11:13 [entrez] PHST- 2023/06/14 00:00 [pmc-release] AID - 10.1007/s10067-023-06649-x [pii] AID - 6649 [pii] AID - 10.1007/s10067-023-06649-x [doi] PST - ppublish SO - Clin Rheumatol. 2023 Sep;42(9):2321-2334. doi: 10.1007/s10067-023-06649-x. Epub 2023 Jun 14.